Skip to main content
×
×
Home

Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension

  • Ylva Ginsberg (a1) and Nils Lindefors (a1)
Abstract
Background

Attention-deficit hyperactivity disorder (ADHD) is highly prevalent in prison inmates, but pharmacological treatment has not yet been evaluated in this group.

Aims

To evaluate osmotic-release oral system (OROS) methylphenidate in adult male long-term prison inmates with ADHD.

Method

Randomised, double-blind, placebo-controlled 5-week trial, followed by 47-week open-label extension in 30 prison inmates with ADHD and comorbid disorders. Primary outcome was level of ADHD symptoms after 5 weeks, evaluated by a masked assessor. Secondary outcomes were self-reported ADHD symptoms, global severity and global functioning throughout the 52-week trial, and post hoc treatment response and numbers needed to treat (NNT) (trial registration: NCT00482313.)

Results

Treatment significantly improved ADHD during the trial (P<0.001; Cohen's d = 2.17), with reduced symptom severity and improved global functioning. The placebo response, cardiovascular measures and adverse events were non-significant; the NNT was 1.1. Attention-deficit hyperactivity disorder symptoms, global severity and global functioning continued to improve during the open-label extension.

Conclusions

Osmotic-release oral system methylphenidate is an effective treatment for adult male prison inmates with ADHD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension
      Available formats
      ×
Copyright
Corresponding author
Ylva Ginsberg, Psychiatry Southwest, M59, Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden. Email: ylva.ginsberg@ki.se
Footnotes
Hide All

Declaration of interest

Y.G. has served as an investigator for Janssen-Cilag, and as a consultant and speaker for Janssen-Cilag and Novartis.

Footnotes
References
Hide All
1 Simon, V, Czobor, P, Bálint, S, Mészáros, A, Bitter, I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194: 204–11.
2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
3 Biederman, J, Mick, E, Faraone, SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816–8.
4 Kessler, RC, Adler, L, Ames, M, Barkley, RA, Birnbaum, H, Greenberg, P, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ 2005; 47: 565–72.
5 Hammerness, P, Surman, C, Miller, K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep 2008; 8: 484–9.
6 Rosler, M, Casas, M, Konofal, E, Buitelaar, J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 2010; 5: 684–98.
7 Eme, RF. Attention-deficit/hyperactivity disorder and correctional health care. J Correct Health Care 2009; 5: 518.
8 Ginsberg, Y, Hirvikoski, T, Lindefors, N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry 2010; 10: 112.
9 Rosler, M, Retz, W, Retz-Junginger, P, Hengesch, G, Schneider, M, Supprian, T, et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004; 254: 365–71.
10 Young, SJ, Adamou, M, Bolea, B, Gudjonsson, G, Muller, U, Pitts, M, et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statment from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry 2011; 11: 32.
11 Gudjonsson, GH, Wells, J, Young, S. Personality disorders and clinical syndromes in ADHD prisoners. J Atten Disord 2010; Oct 26 (Epub ahead of print).
12 Young, S, Wells, J, Gudjonsson, G. Predictors of offending among prisoners: the role of attention-deficit hyperactivity disorder and substance use. J Psychopharmacol 2010; Jun 17 (Epub ahead of print).
13 National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE, 2009 (http://guidance.nice.org.uk/CG72/NICEGuidance/).
14 Faraone, SV, Spencer, T, Aleardi, M, Pagano, C, Biederman, J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24–9.
15 Koesters, M, Becker, T, Kilian, R, Fegert, JM, Weinmann, S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23: 733–44.
16 Adler, LA, Spencer, T, McGough, JJ, Jiang, H, Muniz, R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009; 12: 449–59.
17 Bejerot, S, Ryden, EM, Arlinde, CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry 2010; Jun 1 (Epub ahead of print).
18 Rösler, M, Fischer, R, Ammer, R, Ose, C, Retz, W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259: 120–9.
19 Wender, PH, Reimherr, FW, Marchant, BK, Sanford, ME, Czajkowski, LA, Tomb, DA. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2010; 15: 3645.
20 Lobbestael, J, Leurgans, M, Arntz, A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother 2010; 18: 75–9.
21 Hare, RD, Clark, D, Grann, M, Thornton, D. Psychopathy and the predictive validity of the PCL-R: an international perspective. Behav Sci Law 2000; 18: 623–45.
22 Rosler, M, Retz, W, Stieglitz, RD. Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations – benchmarking instruments for international multicentre trials. Pharmacopsychiatry 2010; 43: 92–8.
23 Guy, W. Clinical Global Impressions. US Department of Health and Human Services, 1976.
24 Ramirez, A, Ekselius, L, Ramklint, M. Axis V – Global Assessment of Functioning scale (GAF), further evaluation of the self-report version. Eur Psychiatry 2008; 23: 575–9.
25 Medori, R, Ramos-Quiroga, JA, Casas, M, Kooij, JJ, Niemela, A, Trott, GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63: 981–9.
26 Spencer, T, Biederman, J, Wilens, T, Doyle, R, Surman, C, Prince, J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 456–63.
27 Surman, CB, Monuteaux, MC, Petty, CR, Faraone, SV, Spencer, TJ, Chu, NF, et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J Clin Psychiatry 2010; 71: 1612–6.
28 Buitelaar, JK, Kooij, JJ, Ramos-Quiroga, JA, Dejonckheere, J, Casas, M, van Oene, JC, et al. Predictors of treatment outcome in adults with ADHD treated with OROS methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 554–60.
29 Levin, FR, Evans, SM, Brooks, DJ, Kalbag, AS, Garawi, F, Nunes, EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 3748.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 6
Total number of PDF views: 67 *
Loading metrics...

Abstract views

Total abstract views: 265 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 16th July 2018. This data will be updated every 24 hours.

Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension

  • Ylva Ginsberg (a1) and Nils Lindefors (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *